9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 8

Gender: All

Min Age: 19 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Tumor Response Rate Following Zoledronic Acid (Zometa),  Progression Free Survival (PFS),  Overall Survival (OS),

Interventions: Zometa,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 2015

Completion Date: April 2016

Last  Posted Date: May 24, 2017

Location: University of Alabama at Birmingham, Birmingham, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT01204203

Was this article helpful?
Dislike 0